Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD

September 1, 2026 7:02 AM

Ocugen, Inc. (NASDAQ: OCGN) announced that the first patient has been dosed in its global Phase 3 registrational trial, ArMaDa3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found